Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
8622 | 1166 | 35.3 | 60% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
2664 | 2947 | METHYLSULFONYLMETHANE//LEUKEMIA CELL DIFFERENTIATION//N ACETYL S N METHYLCARBAMOYLCYSTEINE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | LEUKEMIA CELL DIFFERENTIATION | Author keyword | 15 | 88% | 1% | 7 |
2 | DUNN OSTEOSARCOMA CELLS | Author keyword | 3 | 100% | 0% | 3 |
3 | LOW DOSE CYTOSINE ARABINOSIDE | Author keyword | 2 | 40% | 0% | 4 |
4 | BLR1 | Author keyword | 1 | 50% | 0% | 2 |
5 | LEUKEMIC MYELOID CELL DIFFERENTIATION | Author keyword | 1 | 100% | 0% | 2 |
6 | VRT | Address | 1 | 50% | 0% | 2 |
7 | MYELOCYTIC LEUKEMIA | Author keyword | 1 | 33% | 0% | 3 |
8 | MONOCYTIC LEUKEMIA CELLS | Author keyword | 1 | 40% | 0% | 2 |
9 | LRF DIFFERENTIAT PROGRAMME | Address | 1 | 33% | 0% | 2 |
10 | MYELOID LEUKEMIC CELLS | Author keyword | 1 | 33% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | DIFFERENTIATION INDUCING PROTEIN | 15 | 73% | 1% | 11 |
2 | LEUKEMIC BLOOD CELLS | 6 | 80% | 0% | 4 |
3 | LINE HL 60 | 6 | 14% | 3% | 36 |
4 | INDUCED BLR1 EXPRESSION | 4 | 75% | 0% | 3 |
5 | MOLECULAR REGULATORS | 2 | 67% | 0% | 2 |
6 | SPHINGANINE POTENTIATION | 2 | 67% | 0% | 2 |
7 | ERK2 ACTIVATION | 2 | 25% | 1% | 6 |
8 | HEMATOPOIETIC REGULATORY PROTEINS | 2 | 43% | 0% | 3 |
9 | CANCER CHEMOTHERAPY COMPOUNDS | 2 | 26% | 0% | 5 |
10 | RB GENE EXPRESSION | 1 | 50% | 0% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
HUMAN-LEUKEMIC MODELS OF MYELOMONOCYTIC DEVELOPMENT - A REVIEW OF THE HL-60 AND U937 CELL-LINES | 1985 | 631 | 60 | 48% |
The control of hematopoiesis and leukemia: From basic biology to the clinic | 1996 | 94 | 83 | 34% |
Cytokine control of developmental programs in normal hematopoiesis and leukemia | 2002 | 72 | 139 | 23% |
INDUCTION OF TUMOR-CELL DIFFERENTIATION AS A THERAPEUTIC APPROACH - PRECLINICAL MODELS FOR HEMATOPOIETIC AND SOLID NEOPLASMS | 1986 | 128 | 100 | 36% |
USE OF DIFFERENTIATION-INDUCING AGENTS IN THE MYELODYSPLASTIC SYNDROME AND ACUTE NON-LYMPHOCYTIC LEUKEMIA | 1988 | 36 | 20 | 55% |
LEUKEMIC-CELL MATURATION - PHENOTYPIC VARIABILITY AND ONCOGENE EXPRESSION IN HL60 CELLS - A REVIEW | 1988 | 33 | 81 | 52% |
INDUCTION OF DIFFERENTIATION OF HUMAN ACUTE MYELOGENOUS LEUKEMIA-CELLS - THERAPEUTIC IMPLICATIONS | 1983 | 579 | 54 | 54% |
CELL-DIFFERENTIATION AND BYPASSING OF GENETIC-DEFECTS IN THE SUPPRESSION OF MALIGNANCY | 1987 | 129 | 51 | 41% |
THE MOLECULAR CONTROL OF HEMATOPOIESIS - FROM CLONAL DEVELOPMENT IN CULTURE TO THERAPY IN THE CLINIC | 1992 | 9 | 32 | 50% |
HUMAN ACUTE MYELOID-LEUKEMIA LINES - MODELS OF LEUKEMOGENESIS | 1986 | 67 | 80 | 41% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | VRT | 1 | 50% | 0.2% | 2 |
2 | LRF DIFFERENTIAT PROGRAMME | 1 | 33% | 0.2% | 2 |
3 | COE 21TH CENTURY | 1 | 50% | 0.1% | 1 |
4 | DIFERENCIAC CELULAR CANC | 1 | 50% | 0.1% | 1 |
5 | FRE2141 | 1 | 50% | 0.1% | 1 |
6 | ENEP ZARAGOZA | 0 | 33% | 0.1% | 1 |
7 | EQUIPE PHARMACOCHIM MOL | 0 | 33% | 0.1% | 1 |
8 | MED INVEST LIM 62 | 0 | 33% | 0.1% | 1 |
9 | SEZIONE CHIM BIOL | 0 | 15% | 0.2% | 2 |
10 | MED MED MED ONCOL | 0 | 20% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000242722 | HEXAMETHYLENE BISACETAMIDE//MED SCI SLOAN KETTERING//HMBA |
2 | 0.0000120157 | ERYTHROID GENES//THERMOBIOL//ACLARUBICIN |
3 | 0.0000119748 | CANCER PREVENTION EFFICACY//INVOLUCRIN EXPRESSION//CELLULAR MOL TOXICOL PROGRAM |
4 | 0.0000108281 | LEUKEMIC BLAST PROGENITORS//L CFU//500 SHERBOURNE ST |
5 | 0.0000081747 | T LYMPHOCYTE IMMUNOLOGY//CLIN HOSP O NOVOSEL MED MED//MITOGEN INDUCED CELLULAR CYTOTOXICITY |
6 | 0.0000081021 | ACUTE PROMYELOCYTIC LEUKEMIA//PML RAR ALPHA//APL |
7 | 0.0000076862 | AGE RELATED PATHOLOGY//TACT EW//HERZ KREISLAUFZENTRUM D DEN |
8 | 0.0000074410 | T CELL ASSOCIATED ANTIGENS//CD8 ANTIGEN//B CELL NON HODGKIN LYMPHOMA B NHL |
9 | 0.0000074185 | RETRODIFFERENTIATION//BIOCHEM TUMOR BIOL//BIOCHEM TUMOR BIOL OE6411 |
10 | 0.0000068128 | DIFFERENTIATION FACTOR HLDF//BIOL TESTS//EDGERANK |